Company overview

Synergy Pharmaceuticals

Founded in 1992 and headquartered in Chicago, focused on innovative gastrointestinal therapeutics.

Who we are

Science-driven, patient-first

Synergy develops therapies for gastrointestinal diseases, leveraging GC-C agonist science to address unmet needs with rigorous compliance and patient support.

Headquartered at 300 N La Salle Dr Ste 4925, Chicago, Illinois 60654-3485, United States
Decades of experience in GI research and commercialization
Commitment to transparent safety communication and responsible innovation

Mission

Transform the lives of patients with gastrointestinal conditions through innovative, evidence-based therapies.

Values

Integrity, scientific rigor, patient focus, and collaboration with healthcare professionals.

Expertise

GC-C agonist platform powering TRULANCE® and future pipeline candidates.

Important Safety Information — TRULANCE® (plecanatide)

Indication

TRULANCE is indicated for the treatment of adults with chronic idiopathic constipation (CIC) and adults with irritable bowel syndrome with constipation (IBS-C).

Contraindications

TRULANCE is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. Do not use in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings & Precautions

Diarrhea is the most common adverse reaction. If severe diarrhea occurs, suspend dosing and contact a healthcare provider. Safety and efficacy have not been established in patients under 18 years of age; avoid use in pediatric patients.

Additional Information

Use TRULANCE only as prescribed. Discuss all medical conditions, medications, and pregnancy or breastfeeding considerations with a healthcare professional. See product pages for complete details.

View full product overview →